HAPPY WEDNESDAY TO THE STREET.
$X has been X’ed out. US Steel — the century-and-a-quarter-year-old company that traded on the NYSE under the ticker $X for decades — was finally officially acquired by Japan’s Nippon Steel in a $15B deal.
Guess “US” Steel is a bit of a misnomer now…
🟨 | US stocks wavered following the Federal Reserve’s latest interest rate decision: a hold. Shocker…
📈 | One Notable Gainer: Crypto stocks surged after the GENIUS Act passed through the Senate, enabling stablecoins to be pegged to the US dollar. Coinbase $COIN ( ▲ 0.37% ) and Circle $CRCL ( ▲ 9.9% ) soared on the news.
📉 | One Notable Decliner: The bill was another nail in the coffin for payment stocks like Mastercard $MA ( ▼ 0.72% ) and PayPal $PYPL ( ▼ 0.54% ), which already fell earlier in the week as more retail giants explore stablecoin integration.
— Brooks & Cas
Sponsored by BOXABL
BOXABL believes they have the potential to disrupt a massive and outdated trillion-dollar building construction market by bringing assembly line automation to the home industry.
BOXABL homes are built in their Las Vegas factory, folded, shipped on a truck, and then unfolded on site in one hour. They aim to transform home construction, much like how Henry Ford automated car manufacturing – bringing assembly line efficiency and mass production to an artisanal, slow industry.
And they're not just dreaming big; they're delivering:
Initial prototype order delivered to SpaceX in 2020.
Subsequent project order of 156 homes from the Department of Defense completed in 2021.
Now, after implementing what was learned from those prior orders, actively delivering to developers and consumers.
BOXABL reserved Nasdaq ticker symbol $BXBL*!
BOXABL has already raised over $200M from 50,000+ investors since 2020, and recently achieved a significant milestone: raising over 50% of their Reg A+ funding limit!
Like other game-changing companies, you have a chance to invest in BOXABL’s offering at just $0.80/share. All BOXABL crowdfunding will close on June 24th. This includes all accredited and non-accredited offerings.
Invest today before it's too late!
This is the LAST CHANCE to invest in the current BOXABL funding round and claim your bonus shares.
Disclosure: This is a paid advertisement for BOXABL’s Regulation A offering. Please read the offering circular here. This is a message from BOXABL
*Reserving a Nasdaq ticker does not guarantee a future listing on Nasdaq or indicate that BOXABL meets any of Nasdaq's listing criteria to do so.
STOCK HEATMAPS
S&P 500 Heatmap. Credit: Finviz
All Stock Heatmap. Credit: Finviz
Global ADR snapshot. Credit: Finviz
Market Movers
MARVELL, APPLOVIN, ORACLE
$MRVL ( ▼ 4.83% ) Marvell Stock Surges. What Could Keep Its AI Chip Rally Going. (Barron’s)
$APP ( ▲ 0.98% ) AppLovin: EPS And Revenue Start Moving In Opposite Directions (SeekingAlpha)
$ORCL ( ▼ 2.13% ) Oracle Unveils Initiative to Help Companies Sell Tech to the Pentagon (WSJ)
$ZTS ( ▼ 1.34% ) Zoetis downgraded to Hold from Buy at Stifel (TipRanks)
$SRRK ( ▼ 1.42% ) Scholar Rock drug preserves muscle in obesity trial (YF)
OVERHEARD ON THE STREET
CNBC: The Fed held rates steady at 4.25%-4.5%, but reaffirmed plans for two cuts in 2025, amid persistent inflation and slowing growth.
Bloomberg: Caris Life Sciences $CAI ( ▼ 0.04% ) raised $494M in its IPO, pricing above range at $21 per share, with a $5.9B market valuation.
AP: Amazon $AMZN ( ▲ 0.03% ) plans to produce 10,000 robotaxis annually, challenging Waymo $GOOGL ( ▼ 1.53% ) in the self-driving cab market.
Axios: CEO economic sentiment fell to its lowest level since 2020, with over 40% expecting workforce cuts.
CNN: Texas Instruments $TXN ( ▼ 1.21% ) will invest over $60B to build seven US chip plants, creating 60,000+ jobs.
Tomorrow's Trade Idea, Today
MODEL Y IN THE HEADLIGHTS
Tailwinds at the Tailights
Tesla $TSLA ( ▼ 6.79% ) is facing fresh heat in China’s redlining EV market.
Chinese tech giant Xiaomi $XIACY ( ▼ 0.71% ) has pulled forward the release of its highly anticipated YU7 crossover, which is expected to directly rival Tesla’s Model Y.
The launch, originally scheduled for late July, is now expected later this month.
Another SU7 Moment?
This isn’t Xiaomi’s first shot across Tesla’s bow.
Earlier this year, the company’s debut EV, the SU7, outsold the Model 3 in China for months. The China EV market is growing overall, but Tesla is losing share.
Now, Morgan Stanley’s $MS ( ▼ 0.28% ) Adam Jonas is warning that the YU7 could deliver a similar blow, calling it a Ferrari lookalike priced like a VW.
The early release of the YU7 comes at a fragile time for Tesla in China. Insurance registrations — a proxy for deliveries — have slumped nearly 9% year-to-date. That’s in addition to a sharp 30% year-over-year sales decline in May.
Guggenheim expects the slump to continue. It projects Tesla to deliver 360,000 vehicles globally in Q2, well below the consensus of 399,000 — and miles off early expectations of more than 500,000.
EV vs AV
While Tesla doubles down on innovation — think autopilot, robotaxis, humanoid robots, and so on — Xiaomi favors a back-to-basics approach. It just keeps putting out high-quality EVs at low prices.
Tesla has big plans for the future. But right now, Xiaomi seems to be the one speeding up.
Which stock do you think will outperform over the next 12 months?
Sponsored by FinanceBuzz
Hands Down Some Of The Best 0% Interest Credit Cards
Pay no interest until nearly 2027 with some of the best hand-picked credit cards this year. They are perfect for anyone looking to pay down their debt, and not add to it!
Click here to see what all of the hype is about.
ON OUR RADAR
BBC: Debate is intensifying among Trump allies as the president weighs a potential US strike on Iran’s nuclear sites.
CNBC: The FDA approved Gilead’s $GILD ( ▲ 0.03% ) twice-yearly HIV prevention shot, a major milestone amid proposed federal funding cuts.
Reuters: Autodoc’s upcoming IPO is expected to value the German auto parts retailer at up to $2.8B, with shares priced between €58 and €61.
WSJ: The US Supreme Court upheld state bans on transgender treatments for minors in a 6-3 ruling.
BI: Regencell Bioscience, a revenue-less Chinese herbal medicine firm, has surged 60,000% in 2025. Here’s why.
TUESDAY’S POLL RESULTS
Are you bullish or bearish on Tapestry $TPR ( ▲ 2.52% ) over the next 12 months?
▇▇▇▇▇▇ 🐂 Bullish
▇▇▇▇▇▇ 🐻 Bearish
And, in response, you said:
“Sorry, unrelated to today's poll. Yesterday re: Celsius - the Bearish comment - ‘Energy drinks are all the same except for marketing. The durability of any brand on the market tends not to be long.’ For real...? Red Bull launched in 1987. The internet launched in 1989.”
This message is a paid advertisement for Boxabl Inc. The Street Sheet (SS) receives a flat fee from Ad Astra Media totaling up to $5,250. Other than the compensation received for this advertisement sent to subscribers, The Street Sheet and its principals are not affiliated with Boxabl Inc. This advertisement is sponsored by a third-party Reg A crowdfunding issuer and is for informational purposes only. The Street Sheet does not endorse or recommend any specific offering, and this advertisement should not be construed as a recommendation to invest. Investing in securities, including those offered through Reg A crowdfunding, involves risk, including the potential loss of principal. These investments are speculative, illiquid, and may involve a higher degree of risk compared to more traditional investments. The Street Sheet has not verified the information provided by the advertiser, and we encourage readers to conduct their own due diligence and consult with a licensed financial advisor or other qualified professional before making any investment decision. By engaging with this advertisement, you acknowledge that The Street Sheet and its affiliates are not responsible for any decisions or actions taken based on the information provided in this advertisement. All investments carry risks, and past performance is not indicative of future results. Readers should carefully review all information provided by the issuer, including the offering circular and any other available materials, prior to investing. The Street Sheet may receive compensation from the advertiser for promoting this offering. The Street Sheet and its principals do not own any of the stocks or shares mentioned in this email or in the article that this email links to. The Street Sheet is a research service not owned or managed by registered brokers and therefore this site does not make any investment recommendations. The information provided in this newsletter is not guaranteed as to its accuracy or completeness. Each user of SS chooses to do trades at their sole discretion and risk. SS is not responsible for gains/losses that may result in the trading of these securities. This newsletter includes paid advertisements. The source of all third-party content in which SS receives some sort of compensation is clearly and prominently identified herein as "ad", "Sponsored", or “Together With”. Although we have sent you these advertisements, SS does not specifically endorse any third-party product nor is it responsible for the content, the accuracy, or the completeness of the advertisement or the experience with the third-party advertiser. Furthermore, we make no guarantee or warranty about what is in the advertisement. All investments involve risk, losses may exceed the principal invested, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. This communication from The Street Sheet is for informational purposes only. It is not intended to serve as a recommendation to buy, sell, or hold any security and is not an offer or sale of a security. Information contained within should not be perceived as a research report and is not intended to serve as the basis for any investment decision. Any third-party views reflected herein do not reflect the opinion of The Street Sheet. All investments involve risk and the past performance of a security does not guarantee future results or returns. There is always the potential for financial loss when investing in securities or other financial products. The information contained in this newsletter is subject to change without notice, and we do not undertake any obligation to update it. Readers are encouraged to conduct their own research and due diligence and seek advice from licensed professionals regarding their specific financial needs and circumstances. By reading this newsletter, you agree to hold us harmless from any and all losses, liabilities, costs, or expenses arising from your use or reliance on the information provided. There is no warranty as to the accuracy or completeness of the factual matters included in any advertisement or sponsored content in the newsletter. You have not performed any research on any entity, or its business, that advertises or submits any sponsored content. The Street Sheet is reader-supported. When you buy through links on our site, we may earn a commission.
